Polyrizon Ltd. Files Annual Report on Form 20-F
Polyrizon Ltd. (NASDAQ: PLRZ), a promising biotech company dedicated to pioneering intranasal hydrogel technologies, has recently completed its filing of the Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. This report outlines the company's developments and financial performance for the fiscal year that concluded on December 31, 2024.
Accessing the Annual Report
The filed report can be conveniently accessed through the SEC's official website. Shareholders and interested parties are encouraged to review the comprehensive details it contains. Additionally, this report is also available on Polyrizon’s dedicated Investor Relations site, enhancing accessibility for investors seeking vital corporate information.
Shareholder Access to Reports
Polyrizon prioritizes its shareholder engagement and ensures they have the necessary resources at their fingertips. Shareholders can request copies of the Annual Report on Form 20-F free of charge. To obtain a physical or digital copy, they are invited to contact Polyrizon’s Investor Relations Department, reinforcing the company’s commitment to transparency and communication.
Innovative Hydrogel Technology Overview
This innovative company focuses on creating cutting-edge medical hydrogels designed for intranasal delivery. Their specialized hydrogels serve as a protective barrier, aiming to shield the nasal cavity from viruses and allergens. Polyrizon’s proprietary Capture and Contain (C&C) technology utilizes naturally derived components to develop a nasal spray that acts almost like a “biological mask.” This product has the potential to offer significant health benefits by enhancing the body’s defenses against airborne pathogens.
Expansion of Hydrogel Technologies
Beyond its C&C technology, Polyrizon is diligently working on enhancing the bioadhesive properties and retention capabilities of its hydrogels at the nasal application site. This focus aims to improve the delivery of therapeutic agents directly where they are needed, increasing overall therapeutic efficacy in patients.
Future Directions with Trap and Target Technology
In addition to its current product offerings, Polyrizon is exploring an exciting new avenue of research with its Trap and Target (T&T) technology, which is still in early pre-clinical phases. This technology is expected to advance the nasal delivery of active pharmaceutical ingredients (APIs), targeting better clinical outcomes and patient comfort in treatment.
Contact Information for Investors
For further inquiries or detailed information regarding their product lines or company performance, investors are encouraged to reach out directly to the Investor Relations team via email. This line of communication exemplifies Polyrizon’s focus on maintaining strong relationships with its stakeholders.
Frequently Asked Questions
What is Polyrizon Ltd. known for?
Polyrizon Ltd. is recognized for developing innovative intranasal hydrogel technologies aimed at providing protection against airborne viruses and allergens.
How can shareholders access the Annual Report?
Shareholders can access the Annual Report on Form 20-F via the SEC website or Polyrizon’s Investor Relations site. They can also request a copy directly from the company.
What is the Capture and Contain technology?
Capture and Contain (C&C) technology is a unique hydrogel solution designed to form a barrier in the nasal cavity, preventing contact with harmful agents.
Is there a focus on developing new technologies?
Yes, Polyrizon is actively working on the Trap and Target (T&T) technology to enhance the delivery of active pharmaceutical ingredients through nasal sprays.
How can I get in touch with Polyrizon's Investor Relations?
Interested parties can contact Polyrizon’s Investor Relations at IR@polyrizon-biotech.com for any inquiries or information requests.
